carboplatin + fluorouracil + paclitaxel + radiation

This regimen is a combination therapy used primarily for the treatment of locally advanced esophageal cancer. It consists of three chemotherapeutic agents—carboplatin (a platinum-based DNA crosslinker), fluorouracil (an antimetabolite that inhibits thymidylate synthase), and paclitaxel (a microtubule stabilizer)—administered concurrently with external beam radiation therapy. The combination aims to maximize tumor cell kill by exploiting different mechanisms of action and enhancing radiosensitivity. Clinical studies have shown this approach can achieve pathologic complete response rates around 35%, but it is associated with significant toxicity[2][3]. This multimodality regimen is typically considered for patients who are candidates for aggressive local therapy.

Other names

carboplatin, 5-fluorouracil, paclitaxel, and radiationcarboplatin, 5-FU, paclitaxel, and radiotherapy